Limits...
T regulatory cells: aid or hindrance in the clearance of disease?

Coleman CA, Muller-Trutwin MC, Apetrei C, Pandrea I - J. Cell. Mol. Med. (2007 Nov-Dec)

Bottom Line: CD4+ CD25+ T regulatory cells (Tregs) are classified as a subset of T cells whose role is the suppression and regulation of immune responses to self and non-self.Since their discovery in the early 1970s, the role of CD4+ CD25+ Tregs in both autoimmune and infectious disease has continued to expand.In addition, advances made in the purification and manipulation of CD4+ CD25+ Tregs using new cell markers, techniques and antibodies are discussed.

View Article: PubMed Central - PubMed

Affiliation: Department of Microbiology and Immunology, Tulane University Health Sciences Center, New Orleans, LA, USA.

ABSTRACT
CD4+ CD25+ T regulatory cells (Tregs) are classified as a subset of T cells whose role is the suppression and regulation of immune responses to self and non-self. Since their discovery in the early 1970s, the role of CD4+ CD25+ Tregs in both autoimmune and infectious disease has continued to expand. This review examines the recent advances on the role CD4+ CD25+ Tregs may be playing in various diseases regarding progression or protection. In addition, advances made in the purification and manipulation of CD4+ CD25+ Tregs using new cell markers, techniques and antibodies are discussed. Ultimately, an overall understanding of the exact mechanism which CD4+ CD25+ Tregs implement during disease progression will enhance our ability to manipulate CD4+ CD25+ Tregs in a clinically beneficial manner.

Show MeSH

Related in: MedlinePlus

The in vitro treatment of Rh and AGM PBMCs with Daclizumab showed good cross-reactivity of the drug in both species as demonstrated by the dramatic decrease of the CD25 on CD3+ CD4+ T cells. The drug completely blocked the CD25 receptor after 1 hr from the administration.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4401294&req=5

fig05: The in vitro treatment of Rh and AGM PBMCs with Daclizumab showed good cross-reactivity of the drug in both species as demonstrated by the dramatic decrease of the CD25 on CD3+ CD4+ T cells. The drug completely blocked the CD25 receptor after 1 hr from the administration.

Mentions: One additional drug, daclizumab, is a blocking humanized monoclonal antibody to the α-chain of CD25 [174]. Daclizumab is given after transplant surgery to effectively prevent acute graft rejection; however, its long-term side effects are unknown [174, 175]. In a 2 year post-kidney-transplant study, patients receiving a single dose of daclizumab were shown to have decreased numbers of circulating CD4+ CD25+ FoxP3+ Tregs, however, after clearance of the drug Treg levels returned to normal within 8 weeks [175]. In RMs, daclizumab was shown to successfully protect against inflammation and joint degradation in collagen-induced arthritis [176]. In addition, we also showed that daclizumab is capable of blocking CD25+ simian T cells in vitro (Fig. 5).


T regulatory cells: aid or hindrance in the clearance of disease?

Coleman CA, Muller-Trutwin MC, Apetrei C, Pandrea I - J. Cell. Mol. Med. (2007 Nov-Dec)

The in vitro treatment of Rh and AGM PBMCs with Daclizumab showed good cross-reactivity of the drug in both species as demonstrated by the dramatic decrease of the CD25 on CD3+ CD4+ T cells. The drug completely blocked the CD25 receptor after 1 hr from the administration.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4401294&req=5

fig05: The in vitro treatment of Rh and AGM PBMCs with Daclizumab showed good cross-reactivity of the drug in both species as demonstrated by the dramatic decrease of the CD25 on CD3+ CD4+ T cells. The drug completely blocked the CD25 receptor after 1 hr from the administration.
Mentions: One additional drug, daclizumab, is a blocking humanized monoclonal antibody to the α-chain of CD25 [174]. Daclizumab is given after transplant surgery to effectively prevent acute graft rejection; however, its long-term side effects are unknown [174, 175]. In a 2 year post-kidney-transplant study, patients receiving a single dose of daclizumab were shown to have decreased numbers of circulating CD4+ CD25+ FoxP3+ Tregs, however, after clearance of the drug Treg levels returned to normal within 8 weeks [175]. In RMs, daclizumab was shown to successfully protect against inflammation and joint degradation in collagen-induced arthritis [176]. In addition, we also showed that daclizumab is capable of blocking CD25+ simian T cells in vitro (Fig. 5).

Bottom Line: CD4+ CD25+ T regulatory cells (Tregs) are classified as a subset of T cells whose role is the suppression and regulation of immune responses to self and non-self.Since their discovery in the early 1970s, the role of CD4+ CD25+ Tregs in both autoimmune and infectious disease has continued to expand.In addition, advances made in the purification and manipulation of CD4+ CD25+ Tregs using new cell markers, techniques and antibodies are discussed.

View Article: PubMed Central - PubMed

Affiliation: Department of Microbiology and Immunology, Tulane University Health Sciences Center, New Orleans, LA, USA.

ABSTRACT
CD4+ CD25+ T regulatory cells (Tregs) are classified as a subset of T cells whose role is the suppression and regulation of immune responses to self and non-self. Since their discovery in the early 1970s, the role of CD4+ CD25+ Tregs in both autoimmune and infectious disease has continued to expand. This review examines the recent advances on the role CD4+ CD25+ Tregs may be playing in various diseases regarding progression or protection. In addition, advances made in the purification and manipulation of CD4+ CD25+ Tregs using new cell markers, techniques and antibodies are discussed. Ultimately, an overall understanding of the exact mechanism which CD4+ CD25+ Tregs implement during disease progression will enhance our ability to manipulate CD4+ CD25+ Tregs in a clinically beneficial manner.

Show MeSH
Related in: MedlinePlus